The Pharmaceutical Industry Labor-Management Association (PILMA) supports policies that strengthen America’s national security, protect public health, and promote innovation and high-quality job growth in the pharmaceutical industry. As such, any use of Section 232 investigations into pharmaceutical products must be carefully tailored to focus strictly on legitimate national security concerns and patients’ health. Section 232 is a powerful tool intended to safeguard national security, not to disrupt the critical manufacturing base that supports the health and economic well-being of the United States. We urge policymakers to ensure that such investigations do not undermine the U.S. pharmaceutical supply chain or threaten the jobs of the American workers who manufacture essential medicines and treatments. Strong domestic manufacturing is a cornerstone of both national security and public health. America’s pharmaceutical workforce is vital to ensuring access to safe, effective medications and maintaining our healthcare system’s resilience. Therefore, any actions taken under Section 232 must avoid unintended consequences that could weaken American production, jeopardize good jobs, or limit access to life-saving treatments. PILMA remains committed to advancing policies that balance security with economic growth and support the hardworking men and women whose labor drives American innovation and safeguards our nation’s health.
Pharmaceutical Industry Labor-Management Association